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Staphylococcus aureus and Streptococcus pneumoniae are bacteria that commonly 
colonize healthy individuals without causing disease.  Methicillin-resistant S. aureus 
(MRSA), a more virulent type of S. aureus, is carried by a small percentage of people.  
These two bacteria have an adversarial relationship both in vitro and in vivo, with S. 
pneumoniae being able to limit the growth of S. aureus.  It has been hypothesized that the 
relationship between these bacteria may be altered in individuals immunized with the 
pneumococcal conjugate vaccine, raising concerns that vaccinated individuals may be 
more likely to carry MRSA.  Assessing the carriage rate of these bacteria in both 
vaccinated and non-vaccinated individuals may provide important information to support 
or refute this hypothesis.  To facilitate this study, we developed a multiplex Real Time 
Polymerase Chain Reaction (PCR) assay to simultaneously detect S. aureus and S. 
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Staphylococcus aureus is a Gram positive cocci that causes a variety of infections 
in humans and is carried on the skin or in the nares in approximately 33% of 
asymptomatic individuals (The Centers for Disease Control and Prevention (CDC,) 
2016.)  The CDC reports that individuals who carry S. aureus are at a higher risk of 
developing an infection, especially one involving the skin or soft tissue.  S. aureus causes 
infections that range from mild disease (i.e. folliculitis and boils) to severe conditions 
such as endocarditis and toxic shock syndrome that can be fatal.  S. aureus is considered 
to be an opportunistic pathogen, and seeks entrance into the body through a broken 
barrier, like the skin or other mucosal tissue, where it gains access to surrounding tissues 
and the bloodstream (CDC, 2016.)  Methicillin Resistant S. aureus (MRSA) is resistant to 
many of the antibiotics commonly prescribed to treat S. aureus infections, making 
therapy difficult, but critical in the prevention of sepsis or death.  There are two 
categories of MRSA infections, health care-associated MRSA (HA-MRSA) and 
community-associated MRSA (CA-MRSA).  HA-MRSA is associated with individuals 
who were recently hospitalized or have had on-going contact with a hospital or nursing 
home.   It is more common in individuals following surgical procedures, chemotherapy, 
dialysis or the placement of intravenous lines (CDC, 2016a.)  CA-MRSA is acquired by 
otherwise healthy people in the community and is associated with individuals who 
frequently access athletic facilities, daycare centers, prisons and military institutions.  
(CDC, 2016b.)  MRSA is spread by skin to skin contact, contact sports or poor hand 
hygiene.  Approximately two percent of people carry these bacteria in their nares without 
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any sign of illness (CDC, 2016b.)  MRSA infections have become increasingly common 
and are the main cause of hospital infections (Sahebnasagh et al., 2013.) 
Traditional detection and identification of S. aureus is via Gram stain, culture and 
biochemical methods.  Upon staining, the bacteria are seen as Gram positive cocci 
presenting singly, in pairs or clusters. S. aureus is identified in culture by the observation 
and isolation of creamy beta-hemolytic colonies that subsequently test catalase and 
coagulase positive and ferment mannitol. 
Streptococcus pneumoniae is a Gram positive organism that usually groups as 
diplococci and normally inhabits the upper respiratory tract of humans (Shak et al., 2013, 
Tan, 2012 and CDC, 2016c.)   Healthy individuals who are colonized with this bacteria 
are usually asymptomatic.  In immunocompromised individuals, including the elderly and 
children under two years of age, however, S. pneumoniae infection can cause severe 
disease and death.  Pneumonia, bacteremia and meningitis are the main illnesses caused 
by pneumococcal bacteria, with pneumococcal pneumonia being the most prevalent in 
adults, and 36% being community acquired (CDC, 2016c.)  Most strains of S. 
pneumoniae are encapsulated with complex polysaccharides on the surface.  This feature 
is a determinant of pathogenicity and forms the basis for serotype classification.  As of 
2011, 92 serotypes have been documented, most of which can cause serious disease but 
only the 10 most prevalent strains account for approximately 62% of worldwide disease 
(CDC, 2016c.) 
Conventional detection and identification of S. pneumoniae is also by Gram stain, 
culture and biochemical methods.  Microscopically, S. pneumoniae are Gram positive 
diplococci and are often described as being lancet shaped.  In culture, the organism 
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presents with alpha hemolytic zones around colonies on blood-agar plates.  The bacteria 
are Optochin resistant and can also be identified using antibody-antigen agglutination 
tests.   
In 1977, the first polysaccharide pneumococcal vaccine was licensed in the 
United States.  It was replaced six years later by a 23-valent polysaccharide vaccine 
(PPSV23) which is comprised of polysaccharide antigen from 23 pneumococcal bacteria 
types which cause the majority of invasive disease.  In 2000, the United States licensed 
its first pneumococcal conjugate vaccine (PCV7) and was replaced in 2010 by a 13-
valent pneumococcal conjugate vaccine (PCV13.)  It contains the original seven S. 
pneumoniae serotypes in the PCV7 vaccine, plus six more, all of which are conjugated to 
CRM197, a nontoxic variant of diphtheria toxin (CDC, 2016c.)  The CDC has 
vaccination schedule recommendations for all ages and health statuses based on thorough 
immunization studies (Kobayashi et al., 2015.)   
The impact of the PCV13 vaccine is of interest because of the known adversarial 
interaction between S. pneumoniae and S. aureus, and evidence of increased CA-MRSA 
rates which correlate with the period of increased vaccination (Shak et al., 2013.)  The 
purpose of the PCV13 vaccine is to reduce the risk of severe pneumococcal disease but 
studies show that this immunization also alters S. aureus nasal carriage.  Multiple studies 
have shown that, in children, nasal colonization with S. pneumoniae is negatively 
associated with S. aureus carriage (Regev-Yochay et al, 2004.)  These studies also 
suggest that the impact of pneumococcal vaccination on S. aureus colonization should be 
further investigated.  No studies have investigated the relationship between 
pneumococcal vaccination and S. aureus or MRSA carriage in adults. 
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The studies that investigated the inverse association between S. aureus and S. 
pneumoniae carriage used conventional culture techniques which are less sensitive than 
nucleic acid amplification based methods (Buchan & Ledeboer, 2014.)  Hence, we 
propose to more deeply assess this relationship by detecting colonization of S. aureus and 
S. pneumoniae using a multiplex Real Time PCR based assay that detects low levels of 
both bacteria in the same sample.  
Specific genes that serve as unique PCR target sequences for S. aureus, S. 
pneumoniae and methicillin-resistance have previously been described (Endimiani et al., 
2011.)  The nuc gene encodes for the extracellular thermostable nuclease produced by S. 
aureus, with the thermostable nuclease distinguishing S. aureus from other 
Staphylococcus species (Sahebnasagh et al., 2013.)  Nuc gene amplification by PCR is 
considered the gold standard method for the detection of S. aureus (Ali et al., 2014.)  The 
mecA gene encodes for PBP-2a, which is an alternative penicillin-binding protein (Kilic 
et al., 2009) and its detection by PCR is recommended for the identification of MRSA 
(Siripornmongcolchai et al., 2002.)  The lytA gene encodes the autolysin of S. 
pneumoniae, a NAM-amidase (Llull et al., 2006.)  The lytA-CDC assay is the best 
characterized PCR based pneumococcal DNA detection and is the CDC approved 
method.  (Carvalho et al., 2007.)  
 
MATERIALS AND METHODS 
Bacterial strains.  ATCC strains were obtained from the Upper Peninsula Health 
System-Marquette microbiology department and overnight cultures were grown in 
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Tripticase Soy Broth (Remel.)  Bacterial DNA was extracted using Qiagen Midi-Prep kits 
in accordance with manufacturer’s directions.  DNA quantity and quality was assessed 
using the NanoDrop 2000 Spectrophotometer system by ThermoFisher Scientific.  Other 
common nasal bacteria were utilized as controls to assess analytical specificity.  Strains 
included Streptococcus pneumoniae ATCC 49136 and 49619, Staphylococcus aureus 
ATCC BAA977, 25923, 6532 and β-lactamase positive ATCC 29213, MRSA ATCC 
BAA1761, 42 and 43300, Streptococcus pyogenes ATCC 19615, Streptococcus viridans 
ATCC WT, Streptococcus agalactiae ATCC Group B WT, Streptococcus gallolyticus 
ATCC 9809 and 49147, Staphylococcus haemolyticus ATCC 29970, Staphylococcus 
xylosus ATCC 49148, Staphylococcus saprophyticus ATCC 35552 and 49907, 
Staphylococcus epidermidis ATCC 14900, Moraxella catarrhalis ATCC 8176, 
Micrococcus luteus ATCC 49732, Haemophilus influenza ATCC 9006 and Escherichia 
coli ATCC 25922. 
Primer Sets.  Selected primer sets are as follows:  CDC-lytA FP 5’-
ACGCAATCTAGCAGATGAAGCA-3’ and RP 5’-TCGTGCGTTTTAATTCCAGCT-
3’, nuc 1 FP 5’-GGGTTGATACGCCAGAAACG-3’ and RP 5’-
TGATGCTTCTTTGCCAAATGG-3’, mecA 1 FP 5’-
TTAGATTGGGATCATAGCGTCATTAT-3’ and RP 5’-
AATTCCACATTGTTTCGGTCTAAAA-3’, nuc 2 FP 5’-
GTTGCTTAGTGTTAACTTTAGTTGTA-3’ and RP 5’-
AATGTCGCAGGTTCTTTATGTAATTT-3’, mecA 2 FP 5’-
AAATATTATTAGCTGATTCAGGTTAC-3’ and RP 5’-
CGTTAATATTGCCATTATTTTCTAAT-3’, lytA 3 FP 5’-
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CACGAATAACCAACCAAA-3’,  RP 5’-TAGCCAGTGTCATTCTTC-3’ and Probe 5’-
FAM-CAATCGTCAAGCCGTTCTCAATATCAT-3’BHQ1, 
nuc 3 FP 5’-GGTTCTGAAGATCCAACA-3’, RP 5’-GTCTGAATGTCATTGGTTG-3’ 
and Probe 5’-Cy5-AACCGTATCACCATCAATCGCTT-3’BHQ1, 
mecA 3 FP 5’-GGTGTTGGTGAAGATATAC-3’,  RP 5’-GGATCTGTACTGGGTTAA-
3’ and Probe 5’-HEX-CACCTTGTCCGTAACCTGAATCA-3’BHQ1.  These sets are 
listed as numbered primer sets in Table 1 and primer set combinations in Table 2. 
Real time PCR conditions.  Each Sybr Green based PCR assay consisted of 3 μl 
of PCR grade water, 2 μl of primers (0.5 μM final concentration) and 10 μl LightCycler® 
FastStart DNA Master SYBR Green I mixture (Roche.)  The final reaction volume was 
brought to 20 μl with the addition of 5 μl of DNA template.  Real-time PCR was 
performed on a LightCycler® 96 System (Roche) in 96-well plates in accordance with the 
manufacturer’s protocol. Thermal cycling was started with denaturation at 95°C for 10 
min, followed by 45 cycles at 95°C for 10 seconds, 62°C for 10 seconds and 72°C for 10 
seconds.  The amplification process was followed by melting curve analysis, which 
started at 95°C for 10 seconds, decreased to 65°C for 60 seconds and finally increased at 
0.20°C/s to 97°C for one second with the fluorescence signal, at 470/514 nm, 
continuously monitored. 
Single assay and multiplex assay development.  Primer sets, listed in Table 1, 
were initially evaluated for analytical specificity and sensitivity and PCR efficiency in 
single reaction conditions.  Acceptable primer sets were combined and evaluated in 
duplex conditions and triplex conditions if deemed logical.  Different primer set 
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combinations, listed in Table 2, were utilized to achieve a successful multiplex assay.  
The Multiple Primer Analyzer web based analysis tool by ThermoFisher Scientific® was 
used to analyze for primer interactions 
(https://www.thermofisher.com/us/en/home/brands/thermo-scientific/molecular-
biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-
scientific-web-tools/multiple-primer-analyzer.html.)   
Determination of analytical sensitivity and specificity.      Serial 10-fold 
dilutions of known DNA concentrations, extracted from S. pneumoniae, S. aureus and 
MRSA ATCC strains, were prepared and tested in replicates to determine the limit of 
detection (LOD) for the single and duplex assays.  Data analysis was performed using the 
LightCycler® 96 System Software by Roche.  Copy numbers were generated using a 
calculator on a Science Primer website (http://scienceprimer.com/copy-number-
calculator-for-realtime-pcr) based on the molecular weight of the genomes of S. 
pneumoniae (2.09 mbp) (Donati et al., 2010) and S. aureus (2.75 mbp) (Banada et al., 
2012) and the concentration of extracted DNA.  Limit of detection graphs were generated 
from the data by plotting Cq values to the number of DNA copies in the reaction.  
Analytical specificity was determined from the extracted DNA from all available ATCC 
strains of S. pneumoniae, S. aureus and MRSA along with other common nasal 







The primer sets we first selected for detection of S. aureus, S. pneumoniae, and 
methicillin resistance were chosen based on previously published performance 
characterization data (Carvahlo et al., 2007 & Hoegh et al., 2014.)  Identification methods 
based on detection of these genes are considered the gold standard molecular based 
assays for these bacteria.  As the previously described experiments were performed on 
different analytical platforms, we sought to verify their performance characteristics using 
a Roche Light Cycler® 96 with the corresponding manufacturer’s recommended reagents. 
Individual real time PCR experiments for the detection of nuc, lytA, and mecA were 
performed using DNA extracted from positive and negative bacterial control strains.  
As the CDC-lytA assay is the recommended method for detection of low levels of 
S. pneumoniae and utilizes the best characterized primer set of the three chosen for a 
multiplex assay, we selected that primer set first to evaluate the performance 
characteristics of our assay conditions.  PCR amplification curves of samples analyzed 
for the presence of S. pneumoniae using the CDC recommended lytA primers are shown 
in Figure 1a.  The results of this representative experiment show that all samples 
containing S. pneumoniae control DNA had measurable amplification as detected by 
exponential fluorescence and all samples containing negative control DNA did not (Table 
3.)  Serial dilutions of positive control DNA amplification curves showed Cq values that 
were inversely related to the concentration of template DNA.  Next we performed a melt 
curve analysis (MCA) of PCR positive samples to assess the specificity of the amplicon.   
The results of the MCA showed a very similar melt peak for all positive controls with a 
melt temperature that ranged from 79.69 to 80.26 degrees (Figure 1b.) which is within the 
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expected range.  These results suggest that the CDC-lytA assay adapted to our laboratory 
conditions functions within expected parameters.   
We repeated the above experiments for both the selected nuc primer set and the 
selected mecA primer set.  The PCR amplification curves from a representative 
experiment for the detection of S. aureus using the nuc primer set described by Hoegh et 
al are shown in Figure 2a.  Similar to what was seen with the lytA assay, all samples 
containing S. aureus control DNA exhibited detectable amplification and all negative 
control samples did not amplify (Table 3.)  MCA of the positive control samples resulted 
in the production of similar melt peaks with a temperature range of 79.20 to 79.98 
degrees (Figure 2b.) which falls within the predicted range.  These results suggest that the 
nuc assay adapted from the one described by Hoegh et al functions as expected.  We 
repeated this experiment using MRSA control DNA and the mecA primer set described 
by the same group. Samples containing control DNA were analyzed for the presence of 
mecA, and therefore likely methicillin resistance, the results of which are shown in Table 
3.  Samples containing MRSA positive control DNA exhibit positive real time PCR 
amplification and negative controls failed to show amplification, however, the shape of 
the fluorescent amplification curves indicate a less than ideal PCR efficiency (Figure 3a.)  
MCA of the positive samples resulted in a melt peak with a temperature range of 76.37 to 
76.91 (Figure 3b.) which falls within the predicted range.  These results also suggest that 
the mecA assay adapted using this primer set is acceptable. 
As the single primer set real time PCR experiments produced comparable results 
on the Roche LightCycler® 96 as to those previously observed (Carvahlo et al., 2007 & 
Hoegh et al., 2014) we combined primer sets into duplex assays to assess the feasibility 
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of using these in a 3 primer set multiplex assay.  Duplex real time PCR experiments using 
the following primer set combinations were performed: 1. nuc/mecA 2. lytA/nuc 3. 
lytA/mecA.   
Since the assay described previously by Hoegh et al for the detection of MRSA 
used primer set combination 1 listed above we assessed the performance characteristics 
of an assay adapted to the conditions utilized in the uniplex experiments described above.  
Fluorescence amplification curves obtained by duplex PCR analysis of samples that 
contained S. aureus and MRSA control DNA are shown in Figure 4a.  The PCR analysis 
of samples with S. aureus and MRSA positive control DNA resulted in measurable 
amplification.  A single negative control exhibited an amplification curve with a Cq value 
of 40.  We next performed an MCA on the amplification products and the results show 
two distinguishable melt peaks with temperatures similar to those observed in individual 
experiments (Figure 4b.)  The MCA also discerned a considerably different melt 
temperature (74.39 degrees) for the one negative control sample that exhibited late cycle 
amplification suggesting the generation of a nonspecific amplicon, potentially due to 
primer-dimer formation. Initial analysis of this primer set combination suggests that it 
functions as previously described and detects the presence of both S. aureus and MRSA.  
As the main aim of this project was to develop a method to simultaneously detect 
low levels of S. aureus and S. pneumoniae we next selected the lytA/nuc primer set 
combination for a duplex assay assessment.  Fluorescent amplification curves of samples 
analyzed to detect S. pneumoniae and S. aureus control DNA using this primer set 
combination are shown in Figure 5a.  Samples analyzed for the presence of S. 
pneumoniae and S. aureus using positive control DNA resulted in the generation of 
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amplification curves that were similar to those seen using uniplex PCR of the same 
samples.  A single negative control amplified with a Cq value of 32.05.  MCA of the 
positive samples resulted in two indistinguishable melt peaks (Figure 5b.) with 
temperatures similar to those in the individual experiments.  The MCA also showed a 
considerably different melt temperature (76.41 degrees) for the negative control sample. 
Additionally, there is evidence for low levels of nonspecific amplification in the positive 
control samples and the MCA shows this amplification product has a similar melt 
temperature as seen in the negative control.  The nonspecific amplification observed in 
the negative control sample coupled with similar MCA peaks in positive controls 
suggests primer-dimer formation.  The nonspecific amplification seen in the negative 
control was not detected until a very late Cq value and the base fluorescence values of the 
nonspecific amplification products detected in positive controls by MCA are markedly 
lower than the predicted target amplicon peaks.  Combined, these results indicate that the 
duplex assay generates low levels of nonspecific amplification, possibly primer-dimers, 
that does not competitively inhibit detection of the intended target.  Taken together, these 
findings suggest that this primer set combination functions sufficiently well enough to 
detect the presence of S. aureus and S. pneumoniae, but cannot discriminate between 
them by MCA.  As we intended to transition the assay to TaqMan probe-based chemistry, 
which would allow for discrimination based on sequence analysis rather than melt 
temperature, we deemed this primer combination acceptable for the intended use.   
Next we evaluated the performance characteristics of a 3 primer set combination 
multiplex assay for the detection of lytA/nuc/mecA.  Additionally, this experiment was 
run using an annealing temperature gradient that ranged from 62-66 degrees in order to 
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optimize performance and minimize nonspecific amplification.  The assay was performed 
with three known positive DNA samples extracted from S. aureus, S. pneumoniae, and 
MRSA control organisms along with E.coli DNA and a water blank as negative controls 
(Table 3.)  PCR amplification curves of the control samples analyzed using triplex primer 
combination 4 are shown in Figure 6a.  All positive control samples were detected by a 
Cq of 20 using this triple primer combination.  The impact of the varied annealing 
temperatures on the PCR results of positive controls was minimal.  Negative control 
samples analyzed with the same primer combination exhibited nonspecific amplification 
with Cq values in the low 30 range.  The nonspecific amplification was not eliminated in 
samples with higher annealing temperatures.  An MCA of the amplified samples is shown 
in Figure 6b.  The amplicons generated in the positive control samples show two 
indistinguishable melt peaks attributable to the amplification of nuc and lytA target 
sequences, a result expected based on the prior duplex experiment results.  A small melt 
peak that likely represents amplification of mecA is also present.  MCA of the negative 
control samples resulted in a combination of multiple nonspecific melt peaks indicating 
the formation of nonspecific products regardless of the temperature gradient.  Subsequent 
experiments demonstrated that the nonspecific amplification significantly reduced the 
analytical sensitivity of the multiplex assay as compared to uniplex or duplex PCR (data 
not shown). 
To analyze the triple primer set for potential cross-reactivity, the sequences were 
entered into a Multiple Primer Analyzer web based analysis tool provided by 
ThermoFisher Scientific®.  The results of this analysis are annotated in Figure 7.  The 
analysis suggested that the mecA 1 reverse primer potentially dimerizes with the nuc 1 
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forward primer, an interesting finding considering that the primer combination was 
previously utilized to successfully detect MRSA (Hoegh et al, 2014).  The analysis also 
showed that the mecA 1 forward primer potentially dimerizes with and the CDC-lytA 
forward primer, a combination we had not experimentally evaluated. To assess the 
incompatibility of this primer set we next performed a duplex PCR assay that grouped the 
primer sets in combination 3 described above.  Positive control samples contained S. 
pneumoniae and MRSA DNA and negative controls contained S. aureus DNA with a 
water blank.  Positive control samples amplified upon PCR as expected.  The resulting 
amplification curves are shown in Figure 8a.  Two negative control samples exhibited 
positive amplification.  MCA resulted in multiple melt peaks that do not consistently 
correspond with the predicted outcomes (Figure 8b.)  These results suggest that this mecA 
primer set cross-reacts with the CDC-lytA primers to form primer-dimers in a duplex 
PCR and that this nonspecific amplification is the likely cause of the false positives seen 
in the triplex PCR.  
Given the incompatibility of the mecA primer set described by Hoegh et al with 
the CDC-lytA primer set we performed a literature search for additional mecA primers 
utilized concurrently with a nuc primer set to detect MRSA.  A new selection of primers 
for nuc (Primer set 4) and mecA, (Primer set 5) were selected based on work published by 
Kilic, et al., and the sequences are shown in shown in Table 1.  Initially we chose to 
evaluate the mecA 2 primer set for potential dimerization with the nuc  and CDC-lytA 
primer sets that we previously experimentally evaluated using the Multiple Primer 
Analyzer web based analysis tool.  The results of this analysis suggest the potential for 
cross-reactivity between the mecA 2 forward primer and the CDC-lytA forward primer 
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(Figure 9).  Additionally, the analysis suggested a potential for dimerization between the 
nuc forward and mecA forward primers described by Kilic et al.  This was an interesting 
finding as this primer combination was previously combined to detect MRSA (Kilic et al, 
2009.)  Given that the potential for dimer formation between the CDC-lytA and mecA 2 
appeared lower than that for the nuc/mecA combination we attempted to experimentally 
evaluate the newly selected primers. 
Initially we assessed the performance of a real time PCR assay to detect S. aureus 
control DNA using the nuc primer set described by Kilic et al.  The PCR amplification 
curves from this experiment are shown in Figure 10a.  Samples containing S. aureus 
control DNA resulted in measurable amplification and samples containing negative 
control DNA failed to amplify upon PCR (Table 4.)  An MCA of the positive samples 
reveals a melt peak with a temperature ranging from 79.06 and 79.34 degrees (Figure 
10b.) which falls within the anticipated range.  Next we evaluated the mecA primer set 
described by the same group.  Samples containing control DNA were analyzed for the 
presence of mecA using real time PCR as described above.  PCR analysis of samples 
containing MRSA positive control DNA resulted in amplification while negative controls 
failed to amplify (Figure 11a).  MCA of this PCR shows a melt peak with a temperature 
ranging from 77.32 to 77.61 degrees (Figure 11b.)  These results suggest that the MRSA 
primer sets described by Kilic et al function within acceptable parameters.  
As the single primer set experiments produced comparable results to those 
previously described (Kilic et al, 2009), we combined these new primer sets into a duplex 
assay to determine the feasibility of using them in a 3 primer set based multiplex assay 
with the CDC recommended lytA primer set.  A duplex real time PCR experiment using 
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Primer Set 4 and Primer Set 5 was performed.  The amplification curves of samples 
analyzed by PCR with this combination are shown in Figure 12a.   All analyzed samples 
containing S. aureus and MRSA DNA show detectable amplification.  Four negative 
controls were positive for amplification with Cq values of 34.59, 36.86 and two at 41.5.  
MCA of the positive control samples resulted in a single melt peak with temperatures 
similar to those in the individual experiment for the nuc gene (Figure 12b.)  The 
nonspecific amplification seen in two negative DNA control samples with melt peaks of 
73.82 and 74.13 degrees suggests primer-dimer formation.  Interestingly the predicted 
mecA melt peak at 77 degrees was not detected in analyzed MRSA control samples.  
These results suggest that the nuc/mecA primer combination does not function as 
expected and that mecA is not reliably detected under these conditions.  
As we were unsuccessful in developing a multiplex assay using previously 
characterized primer sets we elected to design novel sets that are intended for multiplex 
compatibility. The three target gene sequences were entered into Premier Biosoft® web 
based software for analysis and multiplex primer design. This software designs primer 
and corresponding probe sequences that are both specific for the targeted sequence and 
theoretically multiplex compatible based on similar annealing temperatures and lack of 
oligo cross-reactivity.  The selected primer sets are shown in Table 1.  Since these primer 
sets are purportedly compatible, instead of first assessing them in uniplex experiments, 
they were evaluated in a triplex real time PCR experiment.  The positive and negative 
control samples are shown in Table 5.  The PCR amplification curves of samples 
analyzed for the presence of S. pneumoniae, S. aureus and MRSA DNA positive control 
samples and non- S. pneumoniae and non-S. aureus negative control samples along with 
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water blanks, using combination primer set 6 are shown in Figure 13a.  All known 
positive samples amplified at a variety of Cqs while the negative DNA controls and water 
blanks amplified at Cq >35.  MCA of the positive control samples resulted in three 
distinguishable melt peaks, however several other melt peaks were seen with the negative 
controls indicating primer dimer formation among these primer sets as well (Figure 13b.)  
Additionally, the MRSA samples should show two melt peaks within the sample for the 
presence of the nuc gene and the mecA gene and only one peak, likely from the mecA 
gene, was present.  Additionally, a TaqMan based version of this multiplex PCR assay 
was attempted several times using the TaqMan probes listed in Table 1 without success 
(data not shown) suggesting that the sequences designed by the Premier Biosoft® web 
based software were not functional or multiplex compatible.  
In order to expedite the assay development process, we elected to develop a Syber 
Green based assay that would simultaneously detect S. pneumoniae and S. aureus and 
discriminate by MCA.  To accomplish this, the lytA primer set designed using Premier 
Biosoft® was chosen as it created an amplicon with higher Tm than the one generated by 
the CDC recommended primers, which was indistinguishable from the Tm of the 
amplicon generated by the nuc primer set.  This primer set was then combined in a 
duplex assay with the nuc 2 primer (Primer Combination 7, Table 2.)   This duplex 
combination was evaluated using positive and negative control DNA samples.  The 
amplification curves of samples analyzed for this experiment are shown in Figure 14a.  
All positive control samples amplified upon PCR while the DNA extracted from non-S. 
pneumoniae and non-S. aureus bacteria and water blanks exhibited no evidence of 
amplification.   MCA showed two distinct melt peaks at the expected temperature ranges 
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that represent a nuc amplicon with a Tm ranging between from 78.24 to 78.94 degrees 
and a lytA amplicon with a Tm between 81.94 to 83.02 degrees (Figure 14b).  The results 
of subsequent identical runs of this PCR setup with the corresponding MCA are shown in 
Figures 14c-f and result in identical outcomes.  Using this assay correctly identified all 24 
positive controls and all 39 negative controls for an analytical specificity of 100%.   To 
assess the analytical sensitivity of this multiplex PCR assay we tested tenfold serial 
dilutions of positive control DNA extracted from positive control organisms.  DNA 
concentrations were experimentally determined by spectrophotometry using a NanoDrop 
2000 and DNA copy numbers were determined mathematically.  PCR Cq values were 
plotted against copy numbers (Figure 15a, b.)  The resulting plots suggest that the LOD 
for both organisms is less than 100 copies but more than 10 copies, a result comparable to 
the limit obtained using single primer pairs (Data not shown).   
Collectively these results suggest that the multiplex PCR assay using these two 
primer sets coupled with an MCA can accurately and repeatedly detect and identify S. 
aureus and S. pneumoniae from the sample. 
  
DISCUSSION 
In this study we sought to develop a multiplexed real time PCR assay to 
simultaneously detect S. aureus, MRSA, and S. pneumoniae in nasal samples. While 
other studies have assessed carriage rates of these bacteria, none previously used nucleic 
acid amplification based assays, but rather used conventional culture based methods 
(Regev-Yochay et al, 2004.)  It is widely accepted that PCR based methods have an 
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improved level of sensitivity when compared to culture and thus, can detect lower levels 
of bacteria.  As such it’s possible these studies under estimated the actual carriage rates.  
At the time this project was initiated no commercially available nucleic acid 
amplification test existed for this purpose.  As such, we initiated a project to develop a 
novel assay designed to detect low level carriage of these organisms in the context of S. 
pneumoniae vaccination.  The original intent was to develop a TaqMan probe based assay 
as this method provides for a high level of specificity based on the combination of unique 
primer and probe sequences.  
The target sequences chosen for PCR based detection of these bacteria were 
selected based on accepted gold standard methods.  To minimize the effort required to 
evaluate the specificity of the proposed assay we elected to initially attempt to 
incorporate previously well characterized primer and probe sets.  The primer set 
recommended for detection of S. pneumoniae by the U.S. CDC was chosen as it has been 
thoroughly characterized elsewhere (Carvalho et al., 2007.)  This primer set amplifies a 
species specific and conserved sequence of the pneumococcal autolysin gene (Llull et al., 
2006.)  We selected a combination of two primer sets previously evaluated for the 
detection of MRSA by Hoegh et al (Hoegh et al., 2014.)  One primer set from this 
combination amplifies a unique region of the S. aureus thermonuclease gene, which is 
conserved across all characterized isolates of the species.  This gene is considered a 
standard PCR based target for S. aureus identification.  The primer set selected for the 
detection of methicillin resistance was previously used by the same group and detects the 
presence of a conserved sequence in mecA the sequence that encodes PBP-2a, the protein 
that establishes resistance to methicillin and other beta-lactams. 
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A series of experiments were performed to evaluate the selected PCR primer sets 
ability to specifically detect control DNA from ATCC strains of S. pneumoniae, S. 
aureus, and MRSA without amplifying DNA from other control organisms that are 
considered normal nasal flora.  These experiments were performed using a LightCycler® 
96 and a master mix based on Roche LightCycler® FastStart DNA Master SYBR Green I.  
We chose this type of real time PCR chemistry over TaqMan based methods, initially, in 
order to more economically evaluate the selected primer sets.  In this phase of the study 
the intention was to assess the suitability of the selected primers using equipment and 
procedures already established in our laboratory.  Single primer set based experiments 
determined that the previously characterized performance of these assays could be 
replicated under our laboratory conditions.  While an MCA was not a feasible method to 
differentiate the nuc and lytA amplicons, this was not a concern due the intent to adopt 
probe based identification methods.  Subsequent duplex based primer set experiments 
also functioned sufficiently well enough to attempt a triplex PCR assay.  Unfortunately, 
the incorporation of the mecA primer set into the assay generated a significant amount of 
nonspecific amplification that is likely due to primer dimer formation.  This resulted in a 
markedly reduced PCR efficiency and an unacceptable level of analytical sensitivity.  
We elected to attempt to utilize a different combination of primers to detect and 
identify MRSA while retaining the CDC recommended primer set for S. pneumoniae 
detection. Evaluation of these new primer sets suggested they function effectively in 
single primer set conditions.  Unfortunately, multiplex efforts were again unsuccessful 
prompting us to generate novel primers using a web based software product that designs 
primers and probes that are specific for the gene targets of interest and that are 
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theoretically designed to be multiplex compatible.  A triplex assay was attempted based 
on the hypothetical primer set compatibility.  The results were, however, unsuccessful 
due to considerable amplification detected in negative control samples, which suggested 
primer dimer formation and reduced the analytical sensitivity of the assay to an 
unacceptable level. Efforts to utilize the triplex primer set with corresponding TaqMan 
probes also proved unsuccessful. 
As multiple attempts to develop a TaqMan based multiplex assay to 
simultaneously detect S. pneumoniae, S. aureus and methicillin resistance were 
unproductive, we pursued a different approach.  We elected to develop a multiplex real 
time PCR to detect S. pneumoniae and S. aureus in the same sample with the ability to 
reflex to a mecA PCR test for S. aureus positive samples.  This approach allowed us to 
develop a multiplex real time PCR assay that specifically detected S. aureus and S. 
pneumoniae without the creation of nonspecific amplification products that negatively 
impact the assays efficiency or sensitivity.  As the melt temperatures for the two PCR 
amplicons were sufficiently different to allow for discrimination based on MCA, we 
elected to halt the project at this phase to expedite the evaluation of this multiplex method 
independently using samples collected for the detection of the two organisms from 
volunteers.  This evaluation will be described in a separate thesis with the intent to study 
if adults that received the pneumococcal vaccination are more likely to carry S. aureus in 
their nasal cavity when compared to unvaccinated individuals.   
The development of this multiplex assay was initiated to more thoroughly assess 
previous findings.  Studies have shown that when grown together under laboratory 
culture conditions, S. pneumoniae inhibits the growth of S. aureus (Shak et al., 2013.)  
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Interestingly, the routine use of a vaccine the rate of S. pneumoniae infection has been 
administered to children since 2000 (CDC, 2016c.)  The observation that CA-MRSA 
infection rates increased and at the same time of widespread use of the pneumococcal 
vaccine has suggested that there may be a link between the two observations (Regev-
Yochay et al., 2004.)  Supporting this concern are the results of culture studies from 
vaccinated children that showed these children have decreased S. pneumoniae nasal 
carriage and changes in other bacterial flora (Tan, 2012.)  More recently, in 2010, a more 
immunogenic vaccine was approved for use in adults over 50, a group at increased risk 
for MRSA infection (CDC, 2016c.)  There is concern that this vaccination creates a niche 
for increased S. aureus carriage, and maybe a risk factor for MRSA infection.  
To study the impact of pneumococcal vaccine on S. aureus carriage and to further 
characterize the in vivo relationship between the two bacteria we seek to detect nasal 
colonization of each in consenting adults using a method with improved analytical 
sensitivity as compared to conventional culture and biochemical phenotyping. 
Furthermore, assaying for both bacteria in the same volunteer sample using previously 
nucleic acid based methods will reduce bias associated with technologist error in 
interpreting cultures.  The increased analytical sensitivity of nucleic acid amplification 
methods will provide a more accurate assessment of the in vivo relationship between 
these two bacteria.  Additionally, a Real Time PCR based method will increase the power 
of the study and provide useful knowledge on the impact of this vaccine on a major 
community health threat; MRSA at a time when vaccine safety is a major public concern. 
Though we originally sought to develop a TaqMan probe based method to investigate this 
concern we elected to accept a Syber Green based method coupled with MCA.  Future 
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work will include the evaluation of this assay in detecting and identifying S. aureus and 
S. pneumoniae using nucleic acid extraction samples obtained from enriched broth 
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Table 1.  Primer sets used in all assay experimentation. 














































Table 2.  Primer set combinations used in duplex and triplex real-time PCR.  
 
 

































































Table 5.  Organisms used with Primer Set Combination 6. 
  
Organism ATCC Strain lytA nuc mecA nuc/mecA lytA/nuc Triplex lytA/mecA
S. pneumoniae 49619 + - - - + + +
BAA977 - + - + + + -
6538 - + - + + -
BAA1761 - + + + + + +
42 - + + + + +
E. coli 25922 +
S. aureus
MRSA
Organism ATCC Strain nuc mecA nuc/mecA
S. pneumoniae 49619 - - -
S. aureus BAA977 + - +
MRSA BAA1761 + + +







S. pyogenes 19615 +
S. viridans WT +
S. agalactiae Group B WT +
9809 +
49147 +
S. haemolyticus 29970 +
S. xylosus 49148 +
S. epidermidis 14900 +
M. catarrhalis 8176 +







Table 6.  Organisms used with Primer Sets 4 & 6 and Primer Combination 7.  These 





Organism ATCC Strain lytA nuc lytA/nuc
49136 + - +
49619 + - +
BAA977 - + +
25923 - + +
6532 - + +
Beta-lactamase positive 29213 - + +
BAA1761 - + +
43300 - + +
S. pyogenes 19615 - - -
S. viridans WT - - -
S. agalactiae Group B WT - - -
9809 - - -
49147 - - -
S. haemolyticus 29970 - - -
S. xylosus 49148 - - -
S. saprophyticus 35552 - - -
S. epidermidis 14900 - - -
M. catarrhalis 8176 - - -
M. luteus 49732 - - -
H. influenza 9006 - - -










Figure 1a.  Primer Set 1 lytA single assay amplification curves.  S. pneumoniae is 







Figure 1b.  Primer Set 1 lytA single assay melt-curve analysis.  S. pneumoniae is 





Figure 2a. Primer Set 2 nuc single assay amplification curves.  S. aureus is represented in 





Figure 2b.  Primer Set 2 nuc single assay melt-curve analysis.  S. aureus is represented in 





Figure 3a.  Primer Set 3 mecA single assay amplification curves.  S. pneumoniae is 








Figure 3b.  Primer Set 3 mecA single assay melt-curve analysis.  S. aureus is represented 





Figure 4a.  Primer Set Combination 1 nuc/mecA duplex assay amplification curves.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green and negative control 









Figure 4b.  Primer Set Combination 1 nuc/mecA duplex assay melt-curve analysis.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green and negative control 





Figure 5a.  Primer Set Combination 2 lytA/nuc duplex assay amplification curves.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green and negative control 










Figure 5b.  Primer Set Combination 2 lytA/nuc duplex assay SYBR green based Melt-
curve analysis.  S. pneumoniae is represented in blue, S. aureus in red, MRSA in green 






Figure 6a.  Primer Set Combination 4 Triplex Assay Gradient Amplification.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 






Figure 6b.  Primer Set Combination 4 triplex assay gradient melt-curve analysis.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 





nucf with mecr 
nucf 
5-aattccacattgtttcggtgtaaaa-> 
             ||||| |    |   
          <-gcaaagaccgcatagttggg-5 
 
mecf with lytf 
mecf 
5-ttagattgggatcatagcgtcattat-> 
                  || ||||    
               <-acgaagtagacgatctaacgca-5 
Figure 7.  Analysis of potential oligo cross-reactivity using ThermoFisher Scientific® 












Figure 8a.  Primer Set Combination 4 lytA/mecA duplex assay amplification curves.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 




Figure 8b.  Primer Set Combination 4 lytA/mecA duplex assay melt-curve analysis.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 




      Self-Dimers: 
 
1 dimer for: mec2FP 
5-aaatattattagctgattcaggttac-> 
          | | |||| |||| | | 
       <-cattggacttagtcgattattataaa-5 
 
1 dimer for: mec2RP 
     5-cgttaatattgccattattttctaat-> 




               Cross Primer Dimers: 
 
lytAFP with mec2FP 
lytAFP 
5-aaatattattagctgattcaggttac-> 
               || ||||  | 
             <-acgaagtagacgatctaacgca-5 
nuc2FP with mec2FP 
nuc2FP 
5-gttgcttagtgttaactttagttgta-> 
              |||| | | | 
           <-cattggacttagtcgattattataaa-5 
Figure 9.  Analysis of potential oligo cross-reactivity using ThermoFisher Scientific® 





Figure 10a.  Primer Set 4 nuc single assay amplification curves.  S. pneumoniae is 








Figure 10b.  Primer Set 4 nuc single assay melt-curve analysis.  S. pneumoniae is 






Figure 11a.  Primer Set 5 mecA single assay amplification curves.  S. pneumoniae is 








Figure 11b.  Primer Set 5 mecA single assay melt-curve analysis.   S. pneumoniae is 






Figure 12a.  Primer Set Combination 5 nuc/mecA duplex assay amplification curves.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 







Figure 12b.  Primer Set Combination 5 nuc/mecA duplex assay melt-curve analysis.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 





Figure 13a.  Primer Set Combination 6 lytA/nuc/mecA triplex assay amplification curves.  
S. pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 







Figure 13b.  Primer Set Combination 6 lytA/nuc/mecA triplex assay melt-curve analysis.  
S. pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 





Figure 14a.  Primer Set Combination 7 (Plate 1) duplex assay amplification curves.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 






Figure 14b.  Primer Set Combination 7 (Plate 1) duplex assay melt-curve analysis.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 






Figure 14c.  Primer Set Combination 7 (Plate 2) duplex assay amplification curves.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 







Figure 14d.  Primer Set Combination 7 (Plate 2) duplex assay melt-curve analysis.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 





Figure 14e.  Primer Set Combination 7 (Plate 3) duplex assay amplification curves.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 







Figure 14f.  Primer Set Combination 7 (Plate 3) duplex assay melt-curve analysis.  S. 
pneumoniae is represented in blue, S. aureus in red, MRSA in green, negative control 





Figure 15a.  Limit of Detection for Primer Set 6 lytA-S. pneumoniae in a duplex assay 





Figure 15b.  Limit of Detection for Primer Set 4 nuc-S. aureus in a duplex assay with 












































Detecting S. aureus and S. pneumoniae Using Multiplex PCR Analysis on the 
LightCycler® 96 for the nuc and lytA genes 
 
Primers: 
A. Fill a Styrofoam container with ice 
B. Remove all FastStart Essential Green DNA Master, molecular grade water and 
and primers from the freezer and place in the ice bath 
a. Thawed FastStart Essential Green DNA Master I (Roche) and Molecular 
grade water may already be in the refrigerator 
C. Clean all pipettes that you will be using with 5% bleach and then 70% ETOH 
solution prior to starting  
NOTE: Wipe pipettes with 5% bleach and 70% ETOH solution between 
each pipetting step to eliminate the possibility of contamination. No liquid 
bleach or ETOH should be visible on the pipette when aspirating samples. 
D. Make a 1:20 multiplex dilution of the nuc and lytA primers. 
a. The primers have been diluted to a one molar solution 
b. Make a 1:10 working aliquot of forward and reverse primers for each set 
to limit freeze/thaw cycles of the primary primer sets 
i. E.g., add  10 µL of forward primer, 10 µL of reverse primer, and 
80 µL IDTE buffer to a 0.5 mL PCR tube 
c. Mix sufficient volume of the primer sets at a 1:1 ratio from the 1:10 
working stock solutions for your master mix 
i. 2 µL of primer mix is required for each PCR test well 
ii. An additional 4-10 µL should be added to the final volume to 
account for volume lost during pipetting 
1. If 96 wells will  be run, use 100 tests as your factor for 
primer volume 
2. 100*2 = 200 µL, or 100 µL of each primer set 
E. Pipette the all reagents to create the PCR master mix per the following ratios 
where n is the number of tests to be performed plus 2.  
a. Molecular grade water 3 µL * n 
b. Primer mix  2 µL * n 
c. Green DNA Master 10µL * n 
F. Mix all reagents together using a clean pipette tip and aspirating and dispensing 
repeatedly 




A.  Set up a plate template on paper (A-H and 1-12,) writing in samples for each well 
(square) 
a. Include one positive control for each: S. aureus, S. pneumoniae and 
MRSA 
b. Include one negative control, water 
B.  Place extracted patient DNA samples on ice in a Styrofoam container 
a. Keep in order of plate set-up as much as possible to avoid error  
C.  Place positive controls and negative control in a separate container on ice to avoid 
contamination with the patient samples. 
Plate Set-Up 
A.  Fill the clear, plastic container with ice and set a 96-well plate in it. 
B.  Wipe pipettes with 5% bleach and 70% alcohol before beginning.   
C.  Pipette master mix up and down to mix well 
D.  Pipette 15 microliters of master mix into each well 
a. The same pipette tip may be used to do this 
E.  Pipette 5 microliters of patient sample DNA in order of template set up 
a. Pipetting of DNA should be mechanical, being careful to avoid 
contamination 
b. Pipettes should be cleaned with 70% ETOH between samples (not each 
sample,) positive controls and negative controls to avoid contamination 
F.  Pipette 5 microliters of each positive control into corresponding wells 
G.  Don clean gloves 
H.  Pipette 5 microliters of the negative control (H2O) into correct well 
I .  Seal the loaded plate with a LightCycler 96 Sealing Foil 
a. Run the tan plastic spatula over the sealing foil and between the well 
ridges to fully seal the plate. 
b. Place the plate in the make-shift centrifuge (salad spinner) 











LightCycler® 96 Instrument Protocol 
A. Select new from the menu 
Setup    
Run Editor    
Detection Format    
Dyes 1: SYBR Green   
Profile    
Programs    
Temp (°C) Ramp (°C/s) Duration (s) Acquisition Mode 
Pre-incubation    
95 4.4 600 None 
3-Step Amplification    
No. of Cycles: 45    
95 4.4 10 None 
62 2.2 10 None 
72 4.4 10 Single 
Melting    
95 4.4 10 None 
65 2.2 60 None 
97 0.1 1 Continuous 
 
B. Save with today’s date and patientsamples# 
a. Example 10162016_patientsamples1 
 
Melt-curve Analysis 
The experiments displayed lytA melt peak ranges between 81.94 and 83.02 degrees and 
nuc peak ranges between 78.24 and 78.94 degrees.  Samples which amplify can be 
resulted as positive because the specificity of the assay was 100% with no nonspecific 
amplification within the negative controls. 
 
 
 
